Investigation of polyvinylpyrrolidone-catechol-derived chitosan nanoconjugates allowed for kidney-targeted treatment of cisplatin-induced acute kidney injury and nursing care management
Restricted accessResearch articleFirst published online April, 2025
Investigation of polyvinylpyrrolidone-catechol-derived chitosan nanoconjugates allowed for kidney-targeted treatment of cisplatin-induced acute kidney injury and nursing care management
Acute kidney injury (AKI) resulting from cisplatin (Cs) chemotherapy presents a significant challenge in clinical management. The study aimed to fabricate a novel compound Polyvinylpyrrolidone-catechol-derived chitosan nanoconjugates (PCChi-NC) for targeting Cs-induced AKI. Characterization studies utilizing UV-visible spectrophotometry, FT-IR, XRD, and TEM revealed a spherical morphology with diameters ranging from 20 to 60 nm. In vitro assessments utilizing HEK 293 cell lines demonstrated the biocompatibility of PCChi-NC without eliciting toxic effects. Furthermore, PCChi-NC exhibited a notable reduction in Cs-induced cell death in kidney cells, as evidenced by biomarker analysis. Anti-inflammatory analysis of mouse kidney homogenates revealed a decrease in TNF-α and IL-1β levels, indicative of the therapeutic efficacy of PCChi-NC in mitigating Cs-induced kidney inflammation. Moreover, In vivo, experimental analysis was evidenced by stable body weight and histopathological changes in mice. Our findings highlight the potential of PCChi-NC as a promising candidate for targeted therapy in Cs-induced AKI, owing to its unique renal targeting capacity.
HuangHHernandezRGengJ, et al.A porphyrin-PEG polymer with rapid renal clearance. Biomaterials2016; 76: 25–32.
3.
GoASChertowGMFanD, et al.Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med2004; 351(13): 1296–1305. DOI: 10.1056/NEJMoa041031.
4.
Meguid El NahasABelloAK. Chronic kidney disease: the global challenge. Lancet2005; 365(9456): 331–340. DOI: 10.1016/S0140-6736(05)17789-7.
5.
JoSKRosnerMHOkusaMD. Pharmacologic treatment of acute kidney injury: why drugs haven’t worked and what is on the horizon. Clin J Am Soc Nephrol2007; 2: 356–365.
6.
McSweeneyKRGadanecLKQaradakhiT, et al.Mechanisms of cisplatin‐induced acute kidney injury: pathological mechanisms, pharmacological interventions, and genetic mitigations. Cancers2021; 13: 13071572. DOI: 10.3390/cancers13071572.
7.
Gómez-RuizSMaksimović-IvanićDMijatovićS, et al.On the discovery, biological effects, and use of cisplatin and metallocenes in anticancer chemotherapy. Bioinorgan Chem Appl2012; 2012: 140284. DOI: 10.1155/2012/140284.
8.
MandicAHanssonJLinderS, et al.Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem2003; 278: 9100–9106.
9.
OzkokAEdelsteinCL. Pathophysiology of cisplatin-induced acute kidney injury. BioMed Res Int2014; 2014: 967826. DOI: 10.1155/2014/967826.
10.
FangCLouDZhouL, et al.Natural products: potential treatments for cisplatin-induced nephrotoxicity. Acta Pharmacol Sin2021; 42: 1951–1969.
11.
BlancoEShenHFerrariM. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol2015; 33: 941–951.
12.
HuangSZhouLLiMC, et al.Preparation and properties of electrospun poly (vinyl pyrrolidone)/cellulose nanocrystal/silver nanoparticle composite fibers. Materials2016; 9: 9070523. DOI: 10.3390/ma9070523.
13.
StalundIVGrønsethHReinholtFP, et al.Chronic kidney disease from polyvinylpyrrolidone deposition in persons with intravenous drug use. Clin J Am Soc Nephrol2022; 17: 518–526.
14.
RobinsonBVSullivanFMBorzellecaJF, et al.PVP A critical review of the kinetics and toxicology of polyvinylpyrrolidone (povidone). Boca Raton, FL: CRC Press.
15.
DhawanSSinglaAKSinhaVR. Evaluation of mucoadhesive properties of chitosan microspheres prepared by different methods. AAPS PharmSciTech2004; 5(4): e67. DOI: 10.1208/pt050467.
16.
LeeHSchererNFMessersmithPB. Single-molecule mechanics of mussel adhesion. Proc Natl Acad Sci U S A2006; 103: 12999–13003. DOI: 10.1073/pnas.0605552103.
17.
KimKKimKRyuJH, et al.Chitosan-catechol: a polymer with long-lasting mucoadhesive properties. Biomaterials2015; 52: 161–170.
18.
QiaoHSunMSuZ, et al.Kidney-specific drug delivery system for renal fibrosis based on coordination-driven assembly of catechol-derived chitosan. Biomaterials2014; 35: 7157–7171.
19.
WeiHJiangDYuB, et al.Nanostructured polyvinylpyrrolidone-curcumin conjugates allowed for kidney-targeted treatment of cisplatin induced acute kidney injury. Bioact Mater2023; 19: 282–291.
20.
LiXWangQDengG, et al.Porous Se@SiO2 nanospheres attenuate cisplatin-induced acute kidney injury via activation of Sirt1. Toxicol Appl Pharmacol2019; 380: 114704. DOI: 10.1016/j.taap.2019.114704.
21.
AmarasiriSSAttanayakeAPArawwawalaLDAM, et al.Barleria prionitis L. extracts ameliorate doxorubicin-induced acute kidney injury via modulation of oxidative stress, inflammation, and apoptosis. J Tradit Complement Med2023; 13: 500–510.
22.
AbdelghanyAMMenazeaAAIsmailAM. Synthesis, characterization and antimicrobial activity of chitosan/polyvinyl alcohol blend doped with Hibiscus Sabdariffa L. extract. J Mol Struct2019; 1197: 603–609.
23.
ArchanaDSinghBKDuttaJ, et al.In vivo evaluation of chitosan-PVP-titanium dioxide nanocomposite as wound dressing material. Carbohydr Polym2013; 95: 530–539.
24.
ManjuSSreenivasanK. Gold nanoparticles generated and stabilized by water soluble curcumin-polymer conjugate: blood compatibility evaluation and targeted drug delivery onto cancer cells. J Colloid Interface Sci2012; 368: 144–151.
25.
RamaneryFPMansurAAPMansurHS, et al.Biocompatible fluorescent core-shell nanoconjugates based on chitosan/Bi2S3 quantum dots. Nanoscale Res Lett2016; 11: 187. DOI: 10.1186/s11671-016-1417-6.
26.
ChuTLTripathiGParkM, et al.In-vitro and in-vivo biocompatibility of dECM-alginate as a promising candidate in cell delivery for kidney regeneration. Int J Biol Macromol2022; 211: 616–625.
27.
NizzeroSLiFZhangG, et al.Systematic comparison of methods for determining the in vivo biodistribution of porous nanostructured injectable inorganic particles. Acta Biomater2019; 97: 501–512.
28.
YangXYanXYangD, et al.Rapamycin attenuates mitochondrial injury and renal tubular cell apoptosis in experimental contrast-induced acute kidney injury in rats. Biosci Rep2018; 38: BSR20180876. DOI: 10.1042/BSR20180876.
29.
AssafKLealCVDeramiMS, et al.Sciatic nerve repair using poly(ε-caprolactone) tubular prosthesis associated with nanoparticles of carbon and graphene. Brain Behav2017; 7: 755. DOI: 10.1002/brb3.755.
30.
NiDJiangDKutyreffCJ, et al.Molybdenum-based nanoclusters act as antioxidants and ameliorate acute kidney injury in mice. Nat Commun2018; 9(1): 5421. DOI: 10.1038/s41467-018-07890-8.
31.
HavasiABorkanSC. Apoptosis and acute kidney injury. Kidney Int2011; 80: 29–40.
SanzABSanchez-NiñoMDRamosAM, et al.Regulated cell death pathways in kidney disease. Nat Rev Nephrol2023; 19: 281–299.
34.
VanmassenhoveJVanholderRNaglerE, et al.Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Nephrol Dial Transplant2013; 28: 254–273.
35.
ZhangXDonnanPTBellS, et al.Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol2017; 18: 256. DOI: 10.1186/s12882-017-0673-8.
36.
YangCGuoYHuangTS, et al.Asiatic acid protects against cisplatin-induced acute kidney injury via anti-apoptosis and anti-inflammation. Biomed Pharmacother2018; 107: 1354–1362.
37.
RameshGReevesWB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest2002; 110: 835–842.
38.
KissNHamarP. Histopathological evaluation of contrast-induced acute kidney injury rodent models. BioMed Res Int2016; 2016: 3763250. DOI: 10.1155/2016/3763250.
39.
HolditchSJBrownCNLombardiAM, et al.Recent advances in models, mechanisms, biomarkers, and interventions in cisplatin-induced acute kidney injury. Int J Mol Sci2019; 20: 3011. DOI: 10.3390/ijms20123011.
40.
OhGSKimHJShenAH, et al.Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies. Electrol Blood Press2014; 12: 55–65.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
